Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide.

We believe there is minimal cause for concern with LLY stock, which makes it attractive but highly sensitive to adverse events as its current valuation is extremely ...

Jim Cramer Backs Eli Lilly (LLY): Will Its Drug Pipeline Dominate Pharma? An array of pharmaceutical pills with the company's logo on the bottle.